

Substitute for form 1449/PTO & 1449B/PTO		Complete If Known										
FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>												
JUL 13 2005 U.S. PATENT AND TRADEMARK OFFICE												
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 5%;">Application Number</td> <td>10/565,281</td> </tr> <tr> <td>Filing Date</td> <td></td> </tr> <tr> <td>First Named Inventor</td> <td>Fabienne Guehenneux et al.</td> </tr> <tr> <td>Examiner Name</td> <td></td> </tr> <tr> <td>Attorney Docket No.</td> <td>1017753-000214</td> </tr> </table>			Application Number	10/565,281	Filing Date		First Named Inventor	Fabienne Guehenneux et al.	Examiner Name		Attorney Docket No.	1017753-000214
Application Number	10/565,281											
Filing Date												
First Named Inventor	Fabienne Guehenneux et al.											
Examiner Name												
Attorney Docket No.	1017753-000214											
Sheet	1	of 1										

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
/SSI/	<i>PAIN, B., et al., "Long-term in vitro culture and characterisation of avian embryonic stem cells with multiple morphogenetic potentialities", Development Company of Biologists, 1996, pp. 2239-2348, vol. 122, no. 8, Cambridge, GB</i>
/SSI/	<i>DREXLER, I., et al., "Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells", Journal of General Virology, February 1998, pp. 347-352, vol. 79, no. 2, Society for General Microbiology, Reading, GB</i>

Examiner Signature	/Stuart Snyder/	Date Considered	06/26/2007
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

SECOND
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
 (use as many sheets as necessary)

Sheets 1 of 2

Application Number	10/565,281
Filing Date	July 22, 2004
First Named Inventor	Fabienne Guehenneux et al.
Examiner Name	
Attorney Docket No.	1017753-000214

JAN 16 2007

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)
-------------------	-----------------	----------------------	---	-------------------------------------

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	STATUS					
					Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	Abstract

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.										
/SS/	BEUG H., et al., "Chicken Hematopoietic Cells Transformed by Seven Strains of Defective Avian Leukemia Viruses Display Three Distinct Phenotypes of Differentiation," Cell, October 1979, pp. 375-390, vol. 18, MIT										
	SUGIMOTO M., et al., "Characteristics of an attenuated vaccinia virus strain, LC16m0, and its recombinant virus vaccines," Vaccine, 1994, pp. 675-681, vol. 12, no. 8, Butterworth-Heinemann Ltd.										
	MOSS, "Replicating and Host-Restricted Non-Replicating Vaccinia Virus Vectors for Vaccine Development," Dev. Biol. Stand., 1994, pp. 55-63, vol. 82, S. Karger AG, Basel										
	SMITH J.R., et al., "Relicative Senescence: Implications for in Vivo Aging and Tumor Suppression," Science, July 5, 1996, pp. 63-67, vol. 273										
	LIU J.L., et al., "Monoclonal Antibodies Recognizing Normal and Retrovirus-Transformed Chicken Hematopoietic Cells," Virology, 1992, pp. 583-591, vol. 189, Academic Press Inc.										
	GUILHOT C., et al., "The 12S adenoviral E1A protein immortalizes avian cells and interacts with the avian RB product," Oncogene, 1993, pp. 619-624, vol. 8, Macmillan Press Ltd.										
	TARTAGLIA J., et al., "NYVAC: A Highly Attenuated Strain of Vaccinia Virus," Virology, 1992, pp. 217-232, vol. 188, Academic Press, Inc.										
	KAWAGUCHI T., et al., "Establishment and Characterization of a Chicken Hepatocellular Carcinoma Cell Line, LMH ¹ ," Cancer Research, August 15, 1987, pp. 4460-4464, vol. 47										
	SAMARUT J., et al., "Target Cells Infected by Avian Erythroblastosis Virus Differentiate and Become Transformed," Cell, April 1982, pp. 921-929, vol. 28, MIT										
	PAIN B., et al., "Chicken Embryonic Stem Cells and Transgenic Strategies," Cells Tissues Organs, 1999, pp. 212-219, vol. 165, S. Karger AG, Basel										
	EYAL-GILADI H., et al., "From Cleavage to Primitive Streak Formation: A Complementary Normal Table and a New Look at the First Stages of the Development of the Chick," Developmental Biology, 1976, pp. 321-337, vol. 49, Academic Press, Inc.										
	MOSCOVICI C., et al., "Continuous Tissue Culture Cell Lines Derived from Chemically Induced Tumors of Japanese Quail," Cell, May 1977, pp. 95-103, vol. 11, MIT										
	BAHA T., et al., "Formation of a transformed follicle is necessary but not sufficient for development of an avian leukosis virus-induced lymphoma," Proc. Natl. Acad. Sci., January 1985, pp. 213-216, vol. 82, USA										
↓	BLANCHARD T., et al., "Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine," Journal of General Virology, 1998, pp. 1159-1167, vol. 79, Great Britain										
Examiner Signature	/Stuart Snyder/	Date Considered	06/26/2007								

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

SECOND
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
 (use as many sheets as necessary)

Sheet 2 of 2

Application Number	10/565,281
Filing Date	July 22, 2004
First Named Inventor	Fabienne Guehenneux et al.
Examiner Name	
Attorney Docket No.	1017753-000214

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
/SS/	KEMPE C.H., et al., "Smallpox Vaccination of Eczema Patients with a Strain of Attenuated Live <i>Vaccinia</i> (CVI-78)," <i>Pediatrics</i> , December 1968, pp. 980-985, vol. 42, no. 6, www.pediatrics.org
↓	KIM H., et al., "Alterations in p53 and E2F-1 function common to immortalized chicken embryo fibroblasts," <i>Oncogene</i> , 2001, pp. 2671-2682, vol. 20, Nature Publishing Group
↓	KIM H., et al., "Post-transcriptional inactivation of p53 in immortalized murine embryo fibroblast cells," <i>Oncogene</i> , 2001, pp. 3306-3310, vol. 20, Nature Publishing Group

Examiner Signature	/Stuart Snyder/	Date Considered	06/26/2007
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.